Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5380349 | 0.97 | POLB (0.55) | POLBGFERSMN1; SMN2CASP6PABPC1 | |
| SCHEMBL5373745 | 0.90 | POLB (0.49) | POLBGFERSMN1; SMN2CASP6PABPC1 | |
| SCHEMBL5367809 | 0.87 | POLB (0.48) | POLBSMN1; SMN2PABPC1KMT2ALMNA | |
| SCHEMBL5391332 | 0.81 | POLB (0.61) | POLBGFERSMN1; SMN2CASP6PABPC1 | |
| Cp-778875 SCHEMBL1600965 | 0.79 | POLB (0.58) | POLBGFERSMN1; SMN2CASP6PABPC1 | |
| SCHEMBL5375209 | 0.79 | POLB (0.58) | POLBGFERSMN1; SMN2CASP6PABPC1 | |
| SCHEMBL5390814 | 0.79 | POLB (0.58) | POLBGFERSMN1; SMN2CASP6PABPC1 | |
| SCHEMBL5388054 | 0.77 | POLB (0.56) | POLBGFERSMN1; SMN2CASP6PABPC1 | |
| SCHEMBL5386741 | 0.77 | POLB (0.56) | POLBGFERSMN1; SMN2CASP6PABPC1 | |
| SCHEMBL14437715 | 0.77 | POLB (0.56) | POLBGFERSMN1; SMN2CASP6PABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262318-B2 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262318-B2 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262318-B2 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| CN-1930121-A | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER PROD INC (US) | 2007-03-14 | — | — | CN | disclosed |
| EP-1725524-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | Pfizer Products Incorporated (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20060258723-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PFIZER INC | 2006-11-16 | — | — | US | disclosed |
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-10-13 | — | — | US | disclosed |
| WO-2005092845-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | POLB 1807/4885GFER 3619/4885SMN1; SMN2 3404/4885 |
| US-20060258723-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARG, PPARA, PPARD | POLB 2006/4885GFER 2976/4885SMN1; SMN2 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.